An overview of pazopanib in metastatic renal cell carcinoma (mRCC) in Ministry of Health (MOH), Malaysia: A multicentre experience

被引：0
|
作者：
Malwinder, S. [1 ]
Nurazzahra, K. [2 ]
Sandya, S. [2 ]
Chen, M. [1 ]
机构：
[1] Hosp Sultan Ismail, Dept Radiotherapy & Oncol, Johor Baharu, Malaysia
[2] Hosp Kuala Lumpur, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
277P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II efficacy trial of pazopanib in nonclear cell metastatic renal cell cancer (mRCC): PINCR
    Costello, Brian Addis
    Thai Huu Ho
    Burbano, Gabriela Perez
    Hillman, David W.
    Quevedo, Fernando
    Pitot, Henry C.
    Pagliaro, Lance C.
    Bryce, Alan Haruo
    Tan, Winston
    Joseph, Richard Wayne
    Leibovich, Bradley C.
    Castle, Erik P.
    Dronca, Roxana Stefania
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [22] Metastatic renal cell carcinoma (MRCC): Responses to different immunotherapies
    Landonio, G
    Baiocchi, C
    Ferrari, M
    Gottardi, O
    Majno, M
    Scanzi, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 468 - 468
  • [23] Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
    Ekenel, M.
    Karabulut, S.
    Cil, I
    Zirtiloglu, A.
    Aydin, E.
    Tural, D.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (01): : 27 - 33
  • [24] Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Cella, David
    Reeves, James
    Hawkins, Robert
    Guo, Jun
    Nathan, Paul
    Staehler, Michael
    de Souza, Paul
    Merchan, Jaime R.
    Boleti, Ekaterini
    Fife, Kate
    Jin, Jie
    Jones, Robert
    Uemura, Hirotsugu
    De Giorgi, Ugo
    Harmenberg, Ulrika
    Wang, Jinwan
    Sternberg, Cora N.
    Deen, Keith
    McCann, Lauren
    Hackshaw, Michelle D.
    Crescenzo, Rocco
    Pandite, Lini N.
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 722 - 731
  • [25] Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?
    Ronald M. Bukowski
    Current Oncology Reports, 2010, 12 : 77 - 79
  • [26] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience
    Matrana, Marc Ryan
    Shetty, Aditya V.
    Atkinson, Bradley J.
    Xiao, Lianchun
    Corn, Paul G.
    Millikan, Randall E.
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Expression of VHL and SRC in metastatic renal cell carcinoma (mRCC).
    Luo, Jia
    Podolak, Jennifer
    Degnin, Catherine
    Chen, Yiyi
    Robinson, Kyle William
    Pukay, Marina
    Schilling, Amy
    Poage, Cara
    Thomas, George V.
    Ryan, Christopher W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Efficacy and safety of Pazopanib in the treatment of metastatic renal cell carcinoma
    Marmesat Rodas, B.
    Marquez Fernandez, E.
    Quesada Sanz, M. P.
    Guerra Estevez, D.
    Villanueva Jimenez, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 572 - 572
  • [29] 10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).
    Chow, Shien
    Pillai, Manon Rhys
    Galvis, Victoria
    Leach, Rebecca
    Keene, Elizabeth
    Chan, Kevin
    Spencer-Shaw, Andrea
    Thistlethwaithe, Fiona
    Hawkins, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Davis, Ian D.
    Machiels, Jean-Pascal H.
    De Souza, Paul L.
    Rottey, Sylvie
    Hong, Bao-fa
    Epstein, Richard J.
    Baker, Katherine L.
    McCann, Lauren
    Crofts, Theresa
    Pandite, Lini
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 475 - 480
12345